SEARCH:   Advanced

Blood, 6 August 2009, Vol. 114, No. 6, pp. 1270-1275. Prepublished online as a Blood First Edition Paper on April 28, 2009; DOI 10.1182/blood-2009-03-212282. This Article Full Text Full Text (PDF) All Versions of this Article: blood-2009-03-212282v1 114/6/1270    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Google Scholar Articles by Maradei, S. C. Articles by Nucci, M. PubMed PubMed Citation Articles by Maradei, S. C. Articles by Nucci, M. Related Collections Transplantation Free Research Articles Red Cells, Iron, and Erythropoiesis Clinical Trials and Observations Related Article in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  TRANSPLANTATION Serum ferritin as risk factor for sinusoidal obstruction syndrome of the liver in patients undergoing hematopoietic stem cell transplantation Simone Cunha Maradei1, Angelo Maiolino2, Alexandre Mello de Azevedo1, Marta Colares1, Luis Fernando Bouzas1, and Marcio Nucci2 1 Bone Marrow Transplantation Center (CEMO), Instituto Nacional de Câncer (INCA), Rio de Janeiro; and 2 University Hospital, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil Hepatic sinusoidal obstruction syndrome (SOS) is a serious complication in hematopoietic stem cell transplant (HSCT) recipients. To determine the impact of pretransplantation hyperferritinemia on the risk of SOS after HSC transplantation, we retrospectively studied 427 HSCT recipients (179 autologous and 248 allogeneic). Serum ferritin levels were measured before transplantation. Patients with and without a diagnosis of SOS were compared regarding demographics; underlying disease; transplant characteristics; receipt of imatinib, busulfan, total body irradiation, gemtuzumab, vancomycin, acyclovir, or methotrexate; and baseline serum ferritin. Univariate and multivariate (stepwise logistic regression) analyses were performed. SOS was diagnosed in 88 patients (21%) at a median of 10 days (range, 2-29 days) after transplantation. By multivariate analysis, allogeneic HSC transplantation (odds ratio [OR] = 8.25; 95% confidence interval [95% CI], 3.31-20.57), receipt of imatinib (OR = 2.60; 95% CI, 1.16-5.84), receipt of busulfan (OR = 2.18; 95% CI, 1.25-3.80), and ferritin serum level higher than 1000 ng/dL (OR = 1.78; 95% CI, 1.02-3.08) were risk factors for SOS. A ferritin serum level higher than 1000 ng/dL in the pretransplantation period is an independent risk factor for SOS. The results suggest the need for prospective studies addressing the use of iron chelation in the pretransplantation period. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Article in Blood Online: SOS: too many irons in the fire! Marcos de Lima Blood 2009 114: 1137-1138. [Full Text] [PDF] This article has been cited by other articles: M. de Lima SOS: too many irons in the fire! Blood, August 6, 2009; 114(6): 1137 - 1138. [Full Text] [PDF]

	Copyright © 2009 by American Society of Hematology         Online ISSN: 1528-0020